Landiolol hydrochlorideProduct ingredient for Landiolol
- Name
- Landiolol hydrochloride
- Drug Entry
- Landiolol
Landiolol is a rapid-acting beta (β)-1 adrenergic receptor blocker that blocks the positive chronotropic effect of the beta-1 selective agonist norepinephrine.8 It works to reduce the heart rate, myocardial contractility, and conduction velocity.1 Compared to other beta-blockers, landiolol possesses unique pharmacodynamic and pharmacokinetic properties, in that it has a rapid onset and short duration of action, and has a greater affinity for β-1 adrenergic receptors over β-2 receptors.1,2
First approved in Japan in 2002 4 for the treatment of intraoperative tachyarrhythmias,1 landiolol was approved in Canada in April 2024 8 and in the US in November 2024 to treat tachyarrhythmias and perioperative tachycardia, including atrial fibrillation.9
- Accession Number
- DBSALT002156
- Structure
Structure for Landiolol hydrochloride (DBSALT002156)
- Synonyms
- [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl 3-(4-{(2S)-2-hydroxy-3-[{2-[(morpholin-4-ylcarbonyl)amino]ethyl}amino]propoxy}phenyl)propanoate hydrochloride / Benzenepropanoic acid, 4-[(2S)-2-hydroxy-3-[[2-[(4-morpholinylcarbonyl)amino]ethyl]amino]propoxy]-, [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl ester, hydrochloride (1:1) / Landiolol HCl / ONO 1101 HYDROCHLORIDE / ONO-1101 HYDROCHLORIDE